Acadian Asset Management LLC Raises Holdings in Cerus Corporation $CERS

Acadian Asset Management LLC raised its holdings in Cerus Corporation (NASDAQ:CERS) by 112.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,898,621 shares of the biotechnology company’s stock after purchasing an additional 1,005,079 shares during the quarter. Acadian Asset Management LLC owned 0.99% of Cerus worth $2,637,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the 1st quarter worth about $32,000. Millennium Management LLC boosted its stake in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after buying an additional 344,395 shares during the period. AQR Capital Management LLC increased its position in shares of Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after acquiring an additional 1,064,133 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Cerus by 152.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 62,854 shares during the period. Finally, Ieq Capital LLC lifted its holdings in shares of Cerus by 7.0% in the 1st quarter. Ieq Capital LLC now owns 2,320,796 shares of the biotechnology company’s stock worth $3,226,000 after acquiring an additional 151,309 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Trading Down 2.4%

NASDAQ CERS opened at $1.20 on Tuesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.35 and a current ratio of 2.00. The firm has a market cap of $230.04 million, a price-to-earnings ratio of -12.00 and a beta of 1.63. The firm has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $1.35. Cerus Corporation has a one year low of $1.12 and a one year high of $2.24.

Cerus (NASDAQ:CERS) last released its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $60.10 million for the quarter, compared to analyst estimates of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.